MARKET

BNTX

BNTX

BIONTECH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

161.03
+0.33
+0.21%
Opening 09:31 01/27 EST
OPEN
161.93
PREV CLOSE
160.70
HIGH
162.87
LOW
160.75
VOLUME
148.16K
TURNOVER
--
52 WEEK HIGH
464.00
52 WEEK LOW
90.29
MARKET CAP
39.05B
P/E (TTM)
4.695
1D
5D
1M
3M
1Y
5Y
Coronavirus tally: Moderna starts to test an omicron-specific COVID vaccine booster in health adults
Moderna has begun testing an omicron-specific COVID-19 booster in healthy adults, following in the wake of a study announced earlier this week by Pfizer and German partner BioNTech ,the Associated Press reported. The original vaccines still offer good prot...
marketwatch.com · 2h ago
After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial
Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically 
Benzinga · 2h ago
Two-thirds of Omicron COVID cases are reinfections: English study
A new study has found that a vast majority of people recently infected with Omicron variant say they had already had Covid previously - CNBC. Imperial College London’s React study
Seekingalpha · 6h ago
Moderna doses first patient in Omicron-specific COVID-19 vaccine trial
Moderna (NASDAQ:MRNA) has dosed the first patient in a phase 2 trial evaluating an Omicron variant-specific COVID-19 vaccine. The trial will include two cohorts: One who received two doses of
Seekingalpha · 15h ago
COVID SCIENCE-Pfizer, Moderna shots safe during in vitro fertilization; healthy gut bacteria may help prevent long COVID
reuters.com · 18h ago
Israel broadens eligibility for fourth dose of COVID vaccine
Israel broadens eligibility for fourth dose of COVID vaccine
reuters.com · 18h ago
Denmark and Austria become latest European countries to lift COVID restrictions
Following in the recent footsteps of the U.K., Ireland, and the Netherlands, Denmark and Austria say they will rescind some COVID-19 curbs in effect. Austria will end its lockdown on
Seekingalpha · 22h ago
U.S. has shipped 400 mln COVID vaccine doses worldwide -White House
U.S. has shipped 400 mln COVID vaccine doses worldwide -White House
reuters.com · 23h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTX. Analyze the recent business situations of BIONTECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.76%Strong Buy
29.41%Buy
52.94%Hold
5.88%Under-perform
0.00%Sell
Analyst Price Target
The average BNTX stock price target is 305.45 with a high estimate of 447.69 and a low estimate of 168.49.
High447.69
Average305.45
Low168.49
Current 160.70
EPS
Actual
Estimate
3.447.0510.6714.28
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 375
Institutional Holdings: 36.98M
% Owned: 15.25%
Shares Outstanding: 242.52M
TypeInstitutionsShares
Increased
90
6.00M
New
88
2.19M
Decreased
99
5.19M
Sold Out
33
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chief Executive Officer/Management Board
Ugur Sahin
Chief Financial Officer/Chief Operating Officer/Management Board
Sierk Poetting
Chief Compliance Officer/Management Board
Sean Marett
Management Board
Ryan Richardson
Management Board
Oezlem Tuereci
Independent Director/Supervisory Board
Christoph Huber
Independent Director/Supervisory Board
Helmut Jeggle
Independent Director/Supervisory Board
Michael Motschmann
Independent Director/Supervisory Board
Ulrich Wandschneider
No Data
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Webull offers kinds of BioNTech SE - ADR stock information, including NASDAQ:BNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTX stock methods without spending real money on the virtual paper trading platform.